The change in FIB-4 in Japanese patients with type 2 diabetes treated by a fixed-ratio combination therapy of insulin degludec and liraglutide (IDegLira): A retrospective observational study.
Hiroyuki ItoRyota SomeyaShigenori AndoRie ArakiEmiko TsugamiSuzuko MatsumotoHideyuki InoueShinichi AntokuTomoko YamasakiToshiko MoriMichiko ToganePublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)
FRC therapy using IDegLira for the treatment of type 2 diabetes is useful for glycemic control and weight management. In particular, IDegLira may be more effective for lowering FIB-4 than adding unused oral antidiabetic agents or increasing the dose of insulin in GLP-1RA-naïve patients. This article is protected by copyright. All rights reserved.
Keyphrases
- glycemic control
- combination therapy
- type diabetes
- end stage renal disease
- weight loss
- blood glucose
- newly diagnosed
- chronic kidney disease
- ejection fraction
- rheumatoid arthritis
- body mass index
- insulin resistance
- prognostic factors
- peritoneal dialysis
- physical activity
- stem cells
- liver fibrosis
- patient reported outcomes
- ankylosing spondylitis
- mesenchymal stem cells
- skeletal muscle
- patient reported
- body weight